Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

The influence of bacteriocins on resistance to infection by gram-negative bacteria: II. Colicin action, transfer of colicinogeny, and transfer of antibiotic resistance in urinary infections
Abraham I. Braude, J. S. Siemienski
Abraham I. Braude, J. S. Siemienski
View: Text | PDF

The influence of bacteriocins on resistance to infection by gram-negative bacteria: II. Colicin action, transfer of colicinogeny, and transfer of antibiotic resistance in urinary infections

  • Text
  • PDF
Abstract

Dual urinary infections were produced in rats with colicinogenic Escherichia coli CF1, elaborating colicin V in the urine, and colicine-sensitive E. coli 9224 by injecting each organism into the medulla of opposite kidneys. The colicin-sensitive organism was eradicated from the urine of 24.3% of rats and the degree of infection by E. coli 9224 reduced to less than half of the control group. Colicin-resistant mutants of E. coli 9224 were not inhibited in mixed infections with colicin producing E. coli CF1. No evidence of inhibitory activity by colicin V was found in the kidneys. The bladder urine, but not the kidney, was also the site for transfer of colicinogeny between homologous (E. coli) and heterologous (E. coli and Aerobacter aerogenes) species. Episomes controlling colicin V and J + I were transferred within 24 hr after establishing the mixed infection. Since E. coli 9224 was resistant to streptomycin and tetracycline, observations were also made on transmission of multiple drug resistance. Streptomycin and tetracycline resistance was readily transferred to E. coli CF1 within 48 hr in the bladder. These results demonstrate that in urinary infections colicins can kill susceptible bacteria and that bacterial genetic elements are transferred.

Authors

Abraham I. Braude, J. S. Siemienski

×

Usage data is cumulative from September 2025 through September 2026.

Usage JCI PMC
Text version 333 8
PDF 202 4
Scanned page 1,025 2
Citation downloads 180 0
Totals 1,740 14
Total Views 1,754
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts